<DOC>
	<DOCNO>NCT02238860</DOCNO>
	<brief_summary>Entacavir tenofovir two first line therapy chronic hepatitis B . Both agent claim equivalent treatment , head head trial available literature effectiveness HBV Decompensated Cirrhosis . The investigator aim compare safety/efficacy virological response patient HBV Decompensated Cirrhosis .</brief_summary>
	<brief_title>A Trial Comparing Entacavir Tenofovir Patients With HBV Decompensated Cirrhosis</brief_title>
	<detailed_description>The effectiveness entacavir tenofovir prospectively study HBV Decompensated cirrhosis ? This prospective , randomise clinical trial help u well patient management efficacy cost effectiveness .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age ( 18 year 70 year ) Hbv surface antigen positive &gt; 6 month HbeAg ( positive negative ) Hbv DNA 10^3 ALT ULN No evidence HCC Platelets count &gt; 30 thousand CTP score &gt; 7 Hepatic encephalopathy ( grade 1 2 ) No prior Drug resistance Age &lt; 18 year HCC patient Prior drug resistance Current HE &gt; 2 Solid organ transplantation Inadequate hematological function Co infection hepatitis C HIV Autoimmune disorder Pregnancy Breast feed Other hepatic disease Patients immunosuppressant chemotherapy agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>Entacavir</keyword>
	<keyword>enofovir</keyword>
</DOC>